Related Experiment Video
Updated: Aug 28, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
MiR-223 and MiR-186 Are Associated with Long-Term Mortality after Myocardial Infarction
Meyer Elbaz1,2,3, Julien Faccini3, Clémence Laperche1,3
1Department of Cardiology, Rangueil University Hospital, 31400 Toulouse, France.
Insights
Identifying patients at risk after myocardial infarction (MI) is crucial. Circulating microRNAs (miRNAs), specifically miR-223 and miR-186, show promise as biomarkers for predicting long-term mortality risk in MI patients.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Biomarker Discovery
Background:
- Accurate risk stratification after myocardial infarction (MI) is essential for guiding secondary prevention therapies.
- Current biomarkers for predicting adverse events post-MI are limited.
- Circulating microRNAs (miRNAs) are emerging as potential diagnostic and prognostic biomarkers in cardiovascular diseases.
Purpose of the Study:
- To investigate the clinical utility of circulating miRNAs as biomarkers for MI.
- To assess the predictive value of a miRNA panel for long-term mortality risk in patients with documented MI.
Main Methods:
- Analysis of seven circulating plasma miRNAs in 67 MI patients and 80 high-risk controls.
- Multivariate logistic regression to identify miRNAs independently associated with MI.
- Kaplan-Meier survival analysis and Cox regression to evaluate mortality prediction.
Main Results:
- Six circulating miRNAs were independently associated with MI occurrence.
- miR-223 and miR-186 demonstrated reliable prediction of long-term mortality in MI patients.
- miR-223 showed a significant association with mortality risk (HR 1.57, p=0.02) after LVEF adjustment.
Conclusions:
- Circulating miR-223 and miR-186 are promising predictive biomarkers for long-term mortality post-MI.
- These miRNAs may aid in identifying high-risk individuals for targeted secondary prevention strategies.
Abstract:
Background-The identification and stratification of patients at risk of fatal outcomes after myocardial infarction (MI) is of considerable interest to guide secondary prevention therapies. Currently, no accurate biomarkers are available to identify subjects who are at risk of suffering acute manifestations of coronary heart disease as well as to predict adverse events after MI. Non-coding circulating microRNAs (miRNAs) have been proposed as novel diagnostic and prognostic biomarkers in cardiovascular diseases. The aims of the study were to investigate the clinical value of a panel of circulating miRNAs as accurate biomarkers associated with MI and mortality risk prediction in patients with documented MI. Methods and Results-seven circulating plasma miRNAs were analyzed in 67 MI patients and 80 control subjects at a high cardiovascular risk but without known coronary diseases. Multivariate logistic regression analyses demonstrated that six miRNAs were independently associated with MI occurrence. Among them, miR-223 and miR-186 reliably predicted long-term mortality in MI patients, in particular miR-223 (HR 1.57 per one-unit increase, p = 0.02), after left ventricular ejection fraction (LVEF) adjustment. Kaplan-Meier survival analyses provided a predictive threshold value of miR-223 expression (p = 0.028) for long-term mortality. Conclusions-Circulating miR-223 and miR-186 are promising predictive biomarkers for long-term mortality after MI.
